Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals significant net losses and operational challenges, particularly related to Lugano. Despite some positive performance from Honey Pot and future growth expectations, the lack of specific guidance, ongoing divestiture plans, and economic slowdown concerns contribute to a negative sentiment. Additionally, the market cap suggests a moderate reaction, resulting in a likely stock price movement in the negative range of -2% to -8%.
Net Sales (Q3 2025) $472.6 million, up 3.5% year-over-year. The increase was driven by overall growth in the company's subsidiaries, excluding Lugano.
Consolidated Net Sales (Year-to-Date 2025) $1.4 billion, an increase of 8.6% over the prior year or 6.1% excluding the impact of Lugano. Growth was driven by strong performance in the consumer and industrial verticals.
Consumer Vertical Sales (Year-to-Date 2025) Up 3.1%, driven by strong growth at the Honey Pot and additional contributions from 5.11. BOA declined slightly due to exiting a lower-value business in China, but its core business grew double digits.
Industrial Vertical Sales (Year-to-Date 2025) Grew 10.5%, driven primarily by Altor's acquisition of Lifoam. Growth was partially offset by short-term headwinds at Arnold due to geopolitical uncertainty and rare earth supply chain disruptions.
Subsidiary Adjusted EBITDA (Year-to-Date 2025) $257 million, an increase of 5.8% over 2024. Growth was driven by double-digit growth at the Honey Pot and Sterno, as well as Altor's acquisition of Lifoam. Partially offset by challenges at Arnold.
GAAP Net Loss (Q3 2025) $87.2 million, which includes expenses related to the Lugano investigation and Lugano's operations.
Consolidated Net Loss (Year-to-Date 2025) $215 million, which includes a $155 million loss at Lugano.
Public Company Costs and Corporate Management Fees (Year-to-Date 2025) $99.5 million, including more than $37 million of one-time costs associated with the Lugano investigation and restatement.
Cash Used in Operating Activities (Year-to-Date 2025) $54 million, primarily due to costs associated with Lugano's operations and its disposition.
Capital Expenditures (Year-to-Date 2025) $34 million, in line with the prior year, to support sustained growth in subsidiaries.
Cash and Cash Equivalents (End of Q3 2025) $61.1 million, with less than $10 million used on the revolver.
BOA Fit System: Continued significant penetration in multiple applications such as snow sports, cycling, workwear, and protective headwear. Exited lower-value children's market in China to focus on core business, which grew double digits.
The Honey Pot: One of the fastest-growing feminine care brands, driving share gains and category growth with innovative products. Achieved strong double-digit EBITDA growth.
5.11: Adapted to tariff environment with supply chain actions and targeted pricing while selectively investing to broaden brand reach.
Rare Earth Magnetics Market: Arnold is one of the few U.S. producers of samarium cobalt magnets, essential for aerospace and defense. Despite short-term headwinds from export restrictions, long-term demand for secure supply chains is rising.
Sterno: Achieved double-digit EBITDA growth by optimizing sourcing and production locations to navigate tariff challenges.
Altor: Supported industrial vertical growth with the acquisition of Lifoam in 2024.
Leverage Reduction: Focused on deleveraging through organic growth and potential strategic transactions, including opportunistic business sales.
Capital Allocation: Prioritized reducing leverage, investing in growth, and planning to return capital to shareholders efficiently.
Geopolitical Risks and Tariff Environment: The year 2025 was marked by geopolitical risks and a fluid tariff environment, creating uncertainty and volatility that impacted operations and financial performance.
Rare Earth Supply Chain Disruptions: Arnold faced short-term headwinds due to disruptions in the rare earth magnetics market, including intermittent export restrictions, which increased volatility and created challenges in supply chain security.
Lugano Investigation and Bankruptcy: The Lugano investigation and subsequent Chapter 11 bankruptcy proceedings resulted in significant financial losses, including a $155 million year-to-date loss, and incurred over $37 million in one-time costs.
Leverage and Debt Reduction: The company faces high leverage, with a year-end leverage ratio of 5.3x (excluding Lugano). There is a need to deleverage both organically and through potential strategic transactions to mitigate financial risks.
Tariff-Related Uncertainty: Broader tariff-related uncertainty created challenges for subsidiaries like 5.11 and Arnold, requiring supply chain adjustments and pricing strategies to protect performance.
Management Fee Overpayment: The overpayment of cash management fees due to Lugano's results has created financial complexities, though the company expects to recoup these fees by the end of 2026.
Subsidiary Adjusted EBITDA Guidance for 2025: Expected subsidiary adjusted EBITDA range, excluding Lugano, is tightened to between $335 million and $355 million.
2026 Outlook: The company expects to organically deleverage in 2026 through solid growth in subsidiary adjusted EBITDA. No specific guidance for 2026 will be provided until the fourth quarter call.
Leverage Reduction Plan: The company plans to reduce leverage both organically and through value-accretive strategic transactions, including potential opportunistic sales of one or more businesses. The year-end leverage ratio, excluding Lugano, is expected to be around 5.3x. The credit agreement amendment provides flexibility to deleverage in an orderly way, with milestone fees incentivizing faster deleveraging starting June 30, 2026.
Capital Allocation Priorities: The company aims to reduce leverage, invest for growth and long-term value creation, and return capital to shareholders at the appropriate time.
2026 Assumptions: The outlook assumes no incremental material impact from changes in the tariff environment or other macro and geopolitical developments.
Commitment to shareholder returns: The company recognizes the need to drive shareholder returns and is taking steps to position itself to efficiently and prudently return capital to shareholders.
Valuation considerations: The company believes its current valuation represents a significant discount to the intrinsic value of its underlying businesses. If this disconnect persists, it will be factored into decisions regarding the return of capital.
Leverage reduction: The company prioritizes reducing leverage to mitigate risk and ensure long-term financial flexibility, which may influence the timing and scale of share repurchase programs.
Potential share repurchase: Management and the Board have not yet purchased shares following the completion of the restatement due to timing and process constraints. They expect the insider trading window to reopen after filing the 2025 Form 10-K and completing the annual audit.
The earnings call reveals significant net losses and operational challenges, particularly related to Lugano. Despite some positive performance from Honey Pot and future growth expectations, the lack of specific guidance, ongoing divestiture plans, and economic slowdown concerns contribute to a negative sentiment. Additionally, the market cap suggests a moderate reaction, resulting in a likely stock price movement in the negative range of -2% to -8%.
The earnings call summary presents a mixed picture: strong financial metrics with a significant preferred equity raise and growth in Lugano, yet vague guidance and lack of clarity in management's responses during the Q&A. The market's reaction may be tempered by uncertainties in growth forecasts and unclear strategies, despite positive signals like deleveraging efforts and potential sales boosts from brand refreshes. Given the company's market cap and the mixed signals, a neutral stock price movement is likely in the short term.
The earnings call highlighted strong financial performance with significant revenue and EBITDA growth, along with a new $100 million share repurchase program. Despite supply chain and labor challenges, the optimistic guidance and strategic focus on M&A, along with increased consumer vertical EBITDA guidance, present a positive outlook. The market cap suggests moderate sensitivity to these factors, leading to a predicted positive stock movement of 2% to 8%.
CODI's earnings call shows strong financial performance with a 27% rise in adjusted EBITDA and increased guidance, offsetting the loss from Crosman's sale. The company's strategic focus on growth and successful acquisition of HoneyPot, along with strong performances in Lugano and BOA, bolster confidence. Despite some concerns in the industrial segment, the consumer segment's growth is robust. The Q&A reveals optimism about M&A opportunities and leverage management. Considering CODI's market cap, these factors suggest a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.